Home>Investment

Insilico Medicine establishes China technology headquarters in Pudong

english.pudong.gov.cn Updated:2025-01-08

Insilico Medicine, one of the world's most renowned biotechnology companies, announced on Jan 6 its plan to locate its China technology headquarters in Shanghai's Pudong New Area. The conceptual design for the headquarters has been completed, aiming to create a closed-loop ecosystem for life sciences and health management.

The headquarters will serve as a hub for Insilico's global drug discovery efforts, where overseas researchers will report progress. Insilico aims to forge a full-cycle platform integrating bioinformation collection and analysis, pharmaceutical research and development, and clinical diagnosis and treatment in Pudong.

Since its establishment in Pudong in 2019, Insilico has advanced AI-driven drug R&D by leveraging rich interdisciplinary talent, robust infrastructure, and a comprehensive industrial chain. It has 22 pre-clinical drug candidates, 10 of which have entered clinical trials.

Insilico will collaborate with Pudong Development Group to build an automated lab powered by AI decision-making, expanding on its existing six functional islands with AI agents for smoother experimental workflows. The lab will occupy 600-700 square meters and support model training, biological validation, and adaptation disease expansion studies.

In 2024, Insilico saw multiple candidate drugs progress to clinical stages, spanning fields such as fibrosis, inflammation, and oncology. The headquarters will bolster AI-enabled biomedical R&D, deepen local cooperation, and explore AI platform applications in diverse life science applications.